$AIM News

AIM ImmunoTech Enrolls Final Participant In Its Phase 2 Clinical Study Of Ampligen Combined With AstraZeneca's Anti-PD-L1 Immune Checkpoint Inhibitor Imfinzi To Treat Metastatic Pancreatic Cancer

Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $9

AIM ImmunoTech To Present Pre-Clinical Data On Potential Role Of Its Lead Drug Ampligen For Ebola Virus Treatment

AIM ImmunoTech Announcing $2.4M Registered Direct Offering Of 7.5M Shares At $0.325 Each.

AIM ImmunoTech Suspends Equity Distribution Agreement And Terminates Continuous Offering As Of May 19, 2026

AIM ImmunoTech Q1 EPS $(0.69) Down From $(0.05) YoY, Sales $22.000K Miss $100.000K Estimate

AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer

Transcript: Aimia Q1 2026 Earnings Conference Call

AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds

AIM ImmunoTech Announces Final Primary Endpoint Report On Objective Response Rate Data From Phase 2 Trial Evaluating Ampligen, With Topline Results Indicating 50% Objective Response Rate, Including 21% Complete Responses

AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP

AIM ImmunoTech Begins Phase 3 Trial Planning For Pancreatic Cancer Treatment Program

AIM ImmunoTech Provides Routine Update on Annual Filings

Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $10

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

AIMIA PROVIDES UPDATE ON ITS SHARE BUYBACKS

We Might See A Profit From Aimia Inc. (TSE:AIM) Soon

Aimia Q4 Earnings Call Highlights

AIMIA REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS

AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors